International Journal of Clinical Research

Objective To explore and analyze the effects of different doses of erythropoietin (EPO) on the prevention and treatment of anemia in premature infants. Methods This study was conducted in the form of a controlled experiment. Four groups of premature infants were selected as the research subjects, with 62 cases in each group, namely group A, group B, group C and control group. Group A, group B and group C all received EPO treatment, and the doses were controlled at 750 IU/kg, 450 IU/kg and 300 IU/kg per week, respectively. The control group did not use EPO. The reticulocytes (RET) and hemoglobin (HB) of the four groups of premature infants were compared. Results There was no significant difference in the RET index level of premature infants in each group before treatment (P>0.05). At 5 weeks of treatment, the RET index of group A was significantly higher than that of the other three groups (P<0.05). There was no significant difference in the HB index level of premature infants in each group before treatment (P>0.05). After treatment, the HB level of each group decreased. At 5 weeks of treatment, the HB index of group A was significantly higher than that of the other three groups (P<0.05). Conclusion The use of EPO in premature infants can prevent and treat anemia, and high-dose medication is more effective.

Premature infant; Anemia; Erythropoietin